Northwire Canada EditionTuesday, July 14, 2026
Northwire
CYG 0.120 +0.0% MGG 0.330 +0.0% BUFF 0.750 +0.0% TKO 10.75 +7.9% MINK 0.105 +0.0% LCE 0.250 +0.0% AEF 0.160 +0.0% BEM 0.095 +5.6% APMI 0.120 +0.0% LIO 0.130 +0.0% KC 0.255 −5.6% NOVA 0.165 +0.0% RIO 2.68 +2.7% FCI 0.390 +0.0% ADE 0.135 +0.0% CYG 0.120 +0.0% MGG 0.330 +0.0% BUFF 0.750 +0.0% TKO 10.75 +7.9% MINK 0.105 +0.0% LCE 0.250 +0.0% AEF 0.160 +0.0% BEM 0.095 +5.6% APMI 0.120 +0.0% LIO 0.130 +0.0% KC 0.255 −5.6% NOVA 0.165 +0.0% RIO 2.68 +2.7% FCI 0.390 +0.0% ADE 0.135 +0.0%
Production / Operations

Aurora Cannabis to upgrade German facility

ACB · Price

Executive Summary

  • Aurora Cannabis Inc. has announced a multi-year investment into operational upgrades at its Good Manufacturing Practice (GMP) manufacturing facility in Leuna, Germany.
  • The upgrades are designed to increase flower growth capacity, enhance product quality, and drive cost-efficiency by leveraging best practices from Aurora's Canadian facilities.
  • The expansion aims to strengthen supply chain resilience, expand domestic EU GMP certified manufacturing capabilities, and meet growing demand for high-quality medical cannabis in Germany.

Key Details

  • Investment Scope: A five-year investment into operational upgrades at the Leuna, Germany facility.
  • Capacity & Quality Goals: Improvements will increase flower growth capacity and product quality while driving cost-efficiency.
  • Specific Upgrades:
    • Commissioning additional grow rooms.
    • Installation of new irrigation and lighting systems in existing rooms.
    • Transitioning to hang dry and dry trim processes.
  • Strategic Context: Aurora Leuna is one of only three licensed cultivation facilities in Germany, playing a pivotal role in supplying locally grown medical cannabis to the expanding patient base.
  • Product Expansion: The site currently grows cultivars under the IndiMed brand; the expansion will enable the site to grow additional cultivars from Aurora's genetics library.
  • Leadership Commentary: Alex Miller, Executive Vice-President of Operations, Science and Supply Chain, stated the investment marks a significant milestone in operational excellence and long-term growth in Europe.

Notable Quotes

  • "This investment marks a significant milestone in our commitment to operational excellence and long-term growth in Europe. These upgrades will strengthen our supply chain resilience, expand our domestic capabilities in EU GMP certified manufacturing, and position us to best meet the growing demand for high-quality medical cannabis in Europe with precision and efficiency." — Alex Miller, Executive Vice-President of Operations, Science and Supply Chain
Read the original news release →

More from Aurora Cannabis Inc